“…As the only characterized methyltransferase mediating histone H3 lysine 36 trimethylation (H3K36me3) in mammals, Setd2 has been shown to regulate the development and function of non-immune and immune cells through various mechanisms involving regulation of DNA methylation (Baubec et al, 2015;Morselli et al, 2015), histone modifications (Ferrari et al, 2014;Xu et al, 2019;Yuan et al, 2011), intragenic transcriptional initiation (Carrozza et al, 2005;Neri et al, 2017), alternative splicing (de Almeida et al, 2011), mRNA modification (Huang et al, 2019), and protein post-translational modification (Chen et al, 2017;Ji et al, 2019;Yuan et al, 2020). Mutation and changed expression of Setd2 have been reported in colitis and colon cancer, while the role of Setd2 in ILC3s has not been investigated (Liu et al, 2021;Yuan et al, 2017). Using Rorc Cre Setd2 f/f mice of both the wild-type and Rag1 À/À background, we have demonstrated that Setd2 fundamentally regulates the maintenance, subset commitment, and function of ILC3s.…”